Literature DB >> 27134876

Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms.

Dalia Rifaat Al-Sharaky1, Sheren Fouad Younes1.   

Abstract

INTRODUCTION: Diagnosing follicular-patterned thyroid neoplasm can be quiet challenging in some cases, where an immunohistochemical profiling becomes mandatory. Galectin-3 may be a helpful tool for classical PTC diagnosis, but it cannot be considered as a diagnostic marker of malignancy. Glypican-3, in contrast, is not thoroughly studied in thyroid neoplasms. AIM: Determine the sensitivity and specificity of galectin-3 and glypican-3 in diagnosing thyroid carcinoma and follicular-patterned thyroid carcinoma.
MATERIALS AND METHODS: A retrospective study was conducted on archival blocks diagnosed from pathology department between 2010 and 2012 including 17 cases of follicular adenoma, 16 cases of Classic Papillary Thyroid Carcinoma (PTC), 6 cases of Follicular Variant of Papillary Thyroid Carcinoma (FVPTC), 3 cases of follicular carcinoma, 5 cases of medullary carcinoma and 1 case of Hürthle cell carcinoma. The nearby non neoplastic (normal) thyroid follicles present in both adenoma and carcinoma cases were also evaluated. STUDY
DESIGN: Evaluation of both galectin-3 and glypican-3 expression using standard immunohistochemical techniques. STATISTICAL ANALYSIS USED: Descriptive analysis of the variables and statistical significances were calculated by non-parametric chi-square test using the Statistical Package for the Social Sciences version 12.0 (SPSS).
RESULTS: Five (30%) and 4 (24%) out of the 17 studied follicular adenoma cases, were positively stained by galectin-3 and glypican-3 respectively, while 30 (97%) and 25 (81%) cases out of the studied 31 carcinoma cases were positively stained by galectin-3 and glypican-3 respectively. The sensitivity, specificity and diagnostic accuracy of galectin-3 vs. glypican-3 in discrimination between thyroid carcinoma and adenoma was 96.8%, 70.6%, and 87.5%vs. 81% 76.5% and 79% respectively. As for the discrimination between follicular-patterned thyroid carcinoma and follicular adenoma it was 90%, 71% and 78% vs. 90% 76.5% and 82%.
CONCLUSION: Glypican-3 is more specific while galectin-3 is more sensitive in diagnosing thyroid carcinoma while glypican-3 is more specific than galectin-3 in discriminating follicular-patterned neoplasm.

Entities:  

Keywords:  Immunohistochemistry; Thyroid adenoma; Thyroid carcinoma

Year:  2016        PMID: 27134876      PMCID: PMC4843262          DOI: 10.7860/JCDR/2016/18375.7430

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  33 in total

1.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions.

Authors:  A Bartolazzi; A Gasbarri; M Papotti; G Bussolati; T Lucante; A Khan; H Inohara; F Marandino; F Orlandi; F Nardi; A Vecchione; R Tecce; O Larsson
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

2.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Authors:  E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

3.  Glypican-3 expression is silenced in human breast cancer.

Authors:  Y Y Xiang; V Ladeda; J Filmus
Journal:  Oncogene       Date:  2001-11-01       Impact factor: 9.867

4.  Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.

Authors:  P L Fernández; M J Merino; M Gómez; E Campo; T Medina; V Castronovo; X Sanjuán; A Cardesa; F T Liu; M E Sobel
Journal:  J Pathol       Date:  1997-01       Impact factor: 7.996

5.  Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.

Authors:  M F Beesley; K M McLaren
Journal:  Histopathology       Date:  2002-09       Impact factor: 5.087

6.  Immunohistochemical study of glypican 3 in thyroid cancer.

Authors:  Kanako Yamanaka; Yasuhiro Ito; Noriko Okuyama; Katsuhisa Noda; Hitoshi Matsumoto; Hiroshi Yoshida; Akira Miyauchi; Mariana Capurro; Jorge Filmus; Eiji Miyoshi
Journal:  Oncology       Date:  2008-05-30       Impact factor: 2.935

7.  Glypican-3 is overexpressed in human hepatocellular carcinoma.

Authors:  Young Kwan Sung; Sun Young Hwang; Mi Kyung Park; Mohammad Farooq; In Sook Han; Han Ik Bae; Jung-Chul Kim; Moonkyu Kim
Journal:  Cancer Sci       Date:  2003-03       Impact factor: 6.716

8.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

9.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

10.  The investigation of galectin-3 in diseases of the thyroid gland.

Authors:  Rita Beáta Kovács; János Földes; Gábor Winkler; Miklós Bodó; Zoltán Sápi
Journal:  Eur J Endocrinol       Date:  2003-11       Impact factor: 6.664

View more
  2 in total

Review 1.  Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Camilla Virili; Francesco Romanelli; Anna Crescenzi; Luca Giovanella
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

Review 2.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.